

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Haines, et al.
SERIAL NUMBER: 10/621,802 EXAMINER : Not Yet Assigned
FILING DATE: July 16, 2003 ART UNIT : 1614
FOR: ANTI-INFLAMMATORY FORMULATIONS

Mail Stop IDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of Cited Reference C1-20; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 21534-002CIP. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,


Ingrid A. Beattie, Reg. No. 42,306
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY & POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: October 31, 2003

Date of Deposit: October 31, 2003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Haines, et al.
SERIAL NUMBER: 10/621,802 EXAMINER : Not Yet Assigned
FILING DATE: July 16, 2003 ART UNIT : 1614
FOR: ANTI-INFLAMMATORY FORMULATIONS

MAIL STOP IDS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Haines, et al.
U.S.S.N.: 10/621,802

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21534-002CIP.

Respectfully submitted,



Ingrid A. Beattie, Reg. No. 42,306
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY & POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: October 31, 2003

TRA 1847397v1

Date of Deposit: October 31, 2003

Please type a plus sign (+) in this box



Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/621,802
Filing Date	July 16, 2003
First Named Inventor	Haines
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	21534-002CIP

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate
---------------	----------	--------------------------	------------	-------------------------------------	-------	-----------	----------------------------

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
---------------	----------	---------------------------------------	-------------------------------------	---------------------	--------------------

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
/ZF/	C1	Baek, et al., "The Effects of Two New Antagonists of Secretory PLA ₂ on TNF, iNOS, and COX-2 Expression in Activated Macrophages", <i>SHOCK</i> , 12(6):473-478 (1999).
	C2	Beauregard, et al., "Induction of Nitric Oxide Synthase and Over-Production of Nitric Oxide by Interleukin-18 in Cultured Lacrimal Gland Acinar Cells", <i>Exp. Eye Res.</i> , 77(1):109-114 (2003).
	C3	Chen, et al., "A 3D-QSAR Study on Ginkgolides and Their Analogues with Comparative Molecular Field Analysis", <i>Bioorg. Med. Chem. Lett.</i> , 8(11):1291-1296 (1998).
	C4	Fan, et al., "Does Astaxanthin Protect Haematococcus Against Light Damage?", <i>Z. Naturforsch.</i> , C53, pp. 93-100 (1998).
	C5	Fies, et al., "Ginkgo Extract in Impaired Vision—Treatment with Special Extract Egb 761 of Impaired Vision Due to Dry Senile Macular Degeneration", <i>Wien. Med. Wochenschr.</i> , 152(15/16):423-426 (2002).
	C6	Guex-Crosier, "Non-Steroidal Anti-Inflammatory Drugs and Ocular Inflammation", <i>Klin. Monatsbl. Augenheilkd.</i> , 218(5):305-308 (2001).
	C7	Jyonouchi, et al., "Immunomodulating Actions of Carotenoids: Enhancement of In Vitro Antibody Production to T-Dependent Antigens", <i>Nutr. Cancer</i> , 21(1):47-58 (1994).
	C8	Jyonouchi, et al., "Effects of Various Carotenoids on Cloned, Effector-Stage T-Helper Cell Activity", <i>Nutr. Cancer</i> , 26(3):313-324 (1996).
	C9	Kurashige, et al., "Inhibition of Oxidative Injury of Biological Membranes by Astaxanthin", <i>Physiol. Chem. Phys. & Med. NMR</i> , 22(1):27-38 (1990).
	C10	Li, et al., "The Bioavailability of Ginkgolides in Ginkgo Biloba Extracts", <i>Planta Medica</i> , 63(6):563-565 (1997).
	C11	Lobefalo, et al., "Dry Eye in Allergic Conjunctivitis: Role of Inflammatory Infiltrate", <i>Int. J. Immunopathol. Pharmacol.</i> , 12(3):133-137 (1999).
	C12	Morrow, et al., "Increase in Circulating Products of Lipid Peroxidation (F ₂ -Isoprostanes) in Smokers", <i>N.E.J. Med.</i> , 332:1198-1203 (1995).
	C13	Newsholme, et al., "Camp-Specific Phosphodiesterase Inhibitor, Rolipram, Reduces Eosinophil Infiltration Evoked by Leukotrienes or by Histamine in Guinea Pig Conjunctiva", <i>Inflammation</i> , 17(1):25-31 (1993).

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Express Mail No.: EV 312709679 US

Date of Deposit: October 31, 2003

Page 2 of 1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam No.	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
12F1	C14	Okai, et al., "Possible Immunomodulating Activities of Carotenoids in In Vitro Cell Culture Experiments", <i>Int. J. Immunopharmac.</i> , 18(12):753-758 (1996).
	C15	Saponara, et al., "Inhibition of cAMP-Phosphodiesterase by Biflavones of Ginkgo Biloba in Rat Adipose Tissue", <i>J. Nat. Prod.</i> , 61(11):1386-1387 (1998).
	C16	Shaban, et al., "Phosphatidylglycerol Potently Protects Human Retinal Pigment Epithelial Cells Against Apoptosis Induced by A2E, a Compound Suspected to Cause Age-Related Macula Degeneration", <i>Exp. Eye Res.</i> , 75(1):99-108 (2002).
	C17	Vint, et al., "The Gold Anti-Rheumatic Drug Auranofin Governs T Cell Activation by Enhancing Oxygen Free Radical Production", <i>Eur. J. Immunol.</i> , 24(9):1961-1965 (1994).
	C18	Vint, et al., "The Interaction of Auranofin and Buthionine Sulfoximine Blocks Activation of Human Peripheral T Lymphocytes", <i>Cell. Immunol.</i> , 152(1):152-161 (1993).
	C19	Vint, et al., "The Effects of Auranofin on Activation and Interleukin-2 Release from Human Peripheral Blood Mononuclear Cells", <i>Agents and Actions</i> , 40(3/4):209-214 (1993).
	C20	Wang, et al., "Astaxanthin-Rich Algal Meal and Vitamin C Inhibit Helicobacter Pylori Infection in BALB/cA Mice", <i>Antimicrobial Agents and Chemotherapy</i> , 44(9):2452-2457 (2000).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Zohreh Fay/ (10/22/2009)	Date Considered	
-----------------------	---------------------------	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1847392v1